Trials / Completed
CompletedNCT00497159
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Medivation, Inc. · Industry
- Sex
- All
- Age
- 29 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | Placebo TID x 90 days |
| DRUG | Dimebon | Dimebon 20 mg TID x 90 days |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-07-06
- Last updated
- 2015-06-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00497159. Inclusion in this directory is not an endorsement.